• Rapport Therapeutics CEO Abraham Ceesay sold 8,220 shares of common stock on June 29, 2026.
• Sales were priced at USD 39.77 and USD 40.34 per share.
• Directly held stake fell to 548,027 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-292519), on July 01, 2026, and is solely responsible for the information contained therein.